doi: 10.3748/wjg.14.4101 30 KlevenMDJueSEnnsCA
In published preclinical work, Ipamorelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or aldosterone, which separates it from earlier secretagogues like GHRP-2 and GHRP-6.nnOriginally developed by Novo Nordisk in the mid-1990s as NNC 26-0161, it was studied in Phase 2 trials for postoperative ileus before that program was discontinued
This binding triggers the cascade of intracellular events that eventually lead to the activation of the PI3/AKT and MAPT pathways
How Does Ipamorelin Compare to Sermorelin
Each peptide remains sealed in its own vial for correct identification, traceability, and protocol control in laboratory settings
Visceral Fat Reduction: The Single Biggest Clinical Difference This is where the comparison stops being academic